



Know when to hold-em!
Know when to fold-em!
Know where to set stops!
Know when to run!
Never count your portfolio
Until the sells are done..

rhstruthers@gmail.com

519-374-9332

Monthly subscription US\$19.99

I have been commenting inflation is not "transitory" and now Powell agrees. Fed Chair Jerome Powell told Congress on Tuesday that it's "probably a good time to retire that word." Many have taken issue with the verbiage in recent months, given that Powell has acknowledged that inflation is proving more powerful and persistent than expected. As a result of the price pressures, the Fed is now [considering](#) a faster tapering to its asset purchase program, shifting gears to tighter monetary policy. This was probably a bigger factor in yesterday's sell off with traders boosting bets on upcoming interest rate hikes.

Concerns about the Omicron variant have led the U.S. to tighten travel rules, requiring all air travellers entering the country to show a negative COVID-19 test performed within one day of departure. Currently, vaccinated international travellers can present a negative result obtained within three days. The new one-day testing requirement from the CDC would apply to U.S. citizens as well as foreign nationals. It is only a matter of time before all the vaccinated perks are gone and they will coheres you to get the booster and shots 4 and maybe 5. And governments will dream up new ways for new taxes and coheres you to take experimental shots.

A surge in new daily infections and the emergence of the Omicron variant is prompting Greece to institute mandatory vaccinations against corona virus. Residents over 60 years old will be required to get jabbed, or face a monthly €100 (\$114) fine beginning on Jan. 16. The penalty would be added to tax bills and the funds will be given to Greek hospitals fighting the pandemic. Quote: "*It is not a punishment. I would say it is a health fee,*" Greek Prime Minister Kyriakos Mitsotakis declared. Greece is broke no matter what they do.

Omicron, the [WHO says today](#) it is mild and a top official in Botswana — where the strain may have emerged— said 85 per cent of cases didn't show any symptoms at all. I bet they change their tune before long. Covid cases doubled to day in South Africa.



[The FDA's Advisory committee is recommending EUA](#) for Merk's experimental drug, the first Covid pill.

Mentioning FDA, I went back on their site to see if Pfizer/BioNTech provided content lists and labelling for the approved manufacture of Cormanity. "[You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 \(21 CFR 601.12\(f\)\(4\)\).](#)"

[There is still nothing. The FDA has only approved the manufacture](#) of these so called vaccines. They are not yet approved for sale and distribution. It is simply a smoke screen to sell more EUA shots.

Sixth Wave CSE: SIXW OTCQB: SIXWF Recent Price - \$0.25
Entry Price - \$0.50 Opinion - hold

Today SIXW provided an update on its Accelerated Molecularly Imprinted Polymer ("**AMIPs™**") technology relative to SARS-CoV-2 variants of concern, in particular, the B.1.1.529 (Omicron) variant. Following is from their news release.

As previously announced, the AMIPS platform has been proven to be capable of detecting all of the variants of interest tested to date. Screening against the Omicron variant will commence as soon as virus samples are available at the La Ki Shing Institute of virology, SIXW's testing partner.

AMIPs Detection

AMIPs have, to date, shown the potential to be resistant to false negatives (a negative test result in an infected individual) resulting from genetic drift of new variants of the virus. AMIPs bind to the entire virus rather than the comparatively smaller portion of the spike proteins to which antibody tests generally bind. This provides a significantly larger point of contact between AMIPs™ and the virus, as compared to antibody-based techniques. The 50 mutations characterized in the Omicron variant represent a lesser difference relative to the entire structure of the virus than the 32 mutations present in the much smaller spike protein and the receptor-binding domain on which they are concentrated. This is expected to result in AMIPs™ being more effective in accurately detecting mutations of the target virus than antibody-based detection techniques.

B.1.1.529 (Omicron) Variant

The Omicron variant has 50 mutations in total, 32 of which are concentrated on the spike protein and the receptor-binding domain (the part of the spike protein that attaches to the cell receptor (ACE2) and initiates viral uptake into the cell). Several of the mutations are seen in other variants such as Delta and are linked to traits of increased binding affinity to the ACE2 receptor, increased viral loads, enhanced transmissibility, promoted immune escape, and decreased antibody neutralization levels. The combination of mutations represents significant potential for reinfection from the waning of natural and vaccine-induced immunity. Certain experts contend that vaccine makers may have to adapt their products as high rates of virus mutation are maintained. **A similar concern is expressed for other antibody-based technologies such as antigen tests and monoclonal antibody therapies.**

Omicron's overall mutational profile is drastically different from the profile on which current COVID-19 vaccines are based. This suggests a potentially higher transmission advantage. The heavily mutated Omicron COVID-19 variant is likely to spread internationally and poses a very high risk of infection surges that could have "severe consequences" in some places, the World Health Organization said on Monday.

The identification of yet another variant with suspected properties more transmissible and potentially dangerous than previous generations strongly indicates that COVID-19 will be around for a long time and that highly accurate, fast, and affordable testing regimes must become the norm. Ongoing testing is absolutely critical for the safety of the global population as the world attempts to return to a pre-COVID lifestyle.

SIXW continues to maintain its rapid development of AMIPs technology. The Company expects to complete the next development phase in the coming weeks, with a successful outcome leading to validation testing by 3rd party laboratories.

SIXW has a real solution for the testing problems and the inaccurate results that are very common. My concern is – will government and public health want such an accurate test. I think there will be resistance to move from the status quo. SIXW has a couple of people, Dr. Fransen and Hon. Grant Mitchell in the company with political connections, well at least connections in the past. They have very good connections in the US military and working with Canadian Universities. I expect if their new testing products get through all the testing and work as expected, it could get huge traction.

The stock is down on the year quite a bit so could be a tax loss sell candidate and why I have as a hold for now. Lets see how it does in the next few weeks, maybe we get a cheaper buying chance.



Rokmaster Resources
Entry Price - \$0.17

TSXV: RKR

OTCQB: RKMSF

Recent Price - \$0.36

Opinion - hold

Rokmaster announced an updated Mineral Resource Estimate ("MRE") for the Revel Ridge Project, B.C. The database on which the updated 2021 MRE is base and includes data from 378 surface and underground drill holes totalling approximately 68,693 m of diamond drill core. The MRE also includes analytical results from 223 underground chip samples. Surface trench results have been used to constrain the Main Zone outcrop. The data has been reviewed and validated, and the MRE estimated by P&E Mining Consultants Inc.

Mineral Resource Estimate Highlights

- Measured and Indicated ("M&I") Mineral Resource, in all mineralized zones, includes 1.36 million gold equivalent ("AuEq") ounces contained within 6.73 million tonnes with an average grade of 6.27 g/t AuEq.
- Inferred Mineral Resource, in all mineralized zones, includes 1.22 million AuEq ounces contained within 6.00 million tonnes at an average grade of 6.33 g/t AuEq.
- In the 2021 M&I Mineral Resource, the average NSR ("Net Smelter Return") value of \$357 per tonne is 225% higher than the \$110 cut-off.

I was expecting a larger increase in the resource numbers, but the good grades are reported around the same as 2020. They added about 75,000 ounces in the M&I category and much more in the Inferred category of 205,000 ounces. This tells us a lot more drilling will be required and the best chance of adding ounces are probably at depth, since most of the previous drilling had an average depth of only around 130 meters.

Here are the CEO comments from the press release.

John Mirko, President & CEO of Rokmaster stated, *"Our updated Mineral Resource Estimate is another milestone in establishing a potential commercial mining operation at Revel Ridge. Rokmaster has added significant gold ounces in every classification, and the system remains open. Rokmaster's diamond drilling and comprehensive geological and geochemical surveys have developed a promising series of targets well outside of the current Mineral Resource boundaries.*

In addition, our understanding of the controls on thicker and higher-grade mineralized zones has progressed significantly. Changes in that knowledge base will guide surface and underground drill programs in the 2022 exploration season, potentially leading to further expansion of our MRE."

The stock is down quite a bit on the year and any stocks in this situation could face tax loss selling in the next few weeks. Support is around \$0.35. so it will be important for this to hold.



Drone Delivery TSXV:FLT
Entry Price - \$0.43

OTC:TAKOF
Opinion - hold

Recent Price - \$0.84

Today, FLT released an update on the Condor drone development. The company has successfully tested numerous aspects of the Condor solution at test ranges in Alma, Que., at the Unmanned Aerial System Centre of Excellence, and in Foremost, Alta., at the UAS test range. On Nov. 4, 2021, the company announced its Ontario commercialization centre, where Condor testing will continue, in addition to customer per-delivery inspection, maintenance, training and customer demonstrations. The centre will also support testing and development of multiple DDC platforms, including the: FLYTE software, detect and avoid (DAA) systems, Canary drone, DroneSpot depots, etc.

In addition to previously announced updates on Condor development and testing, the following further progress has been made -- engine control unit (ECU) overhaul (avionics + engine overhaul), enhanced start-up procedure process, mechanical reliability improvements, upgraded to latest components (clutch, splitter gearbox, torque valves, etc).

Additionally, some items that remain to be completed - integration of automated weight & balance system, further testing with FLYTE software system, further payload testing, environmental testing, high speed testing, etc.

This Condor is a game change not only in drone delivery but delivery period. That is because of it's large payload of 180 kg and long distance of 200 kms. However, the stock is down on the year and another tax loss selling candidate. There is not much support on the chart until \$0.60. I don't know if it will drop that low?



I find tax loss selling peaks around the middle of December. I will send an alert out if I see some of our picks getting over sold because of this. It is near year end and I will probably sell off a few stocks on our list. Not necessarily ones that are down or for a tax loss, but a few could fit this bill.

Copyright 2021, Struther's Resource Stock Report

All forecasts and recommendations are based on opinion. Markets change direction with consensus beliefs, which may change at any time and without notice. The author/publisher of this publication has taken every precaution to provide the most accurate information possible. The information & data were obtained from sources believed to be reliable, but because the information & data source are beyond the author's control, no representation or guarantee is made that it is complete or accurate. The reader accepts information on the condition that errors or omissions shall not be made the basis for any claim, demand or cause for action. Because of the ever-changing nature of information & statistics the author/publisher strongly encourages the reader to communicate directly with the company and/or with their personal investment adviser to obtain up to date information. Past results are not necessarily indicative of future results. Any statements non-factual in nature constitute only current opinions, which are subject to change. The author/publisher may or may not have a position in the securities and/or options relating thereto, & may make purchases and/or sales of these securities relating thereto from time to time in the open market or otherwise. Neither the information, nor opinions expressed, shall be construed as a solicitation to buy or sell any stock, futures or options contract mentioned herein. The author/publisher of this letter is not a qualified financial adviser & is not acting as such in this publication.